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Introduction   
 
Lung cancer screening with low dose computed tomography (LDCT) saves lives and it is 
only a matter of time before it is embraced by national health organisations throughout 
Europe. The evidence from the NLST trial on reduction in mortality and from seven pilot 
trials within Europe on other aspects of screening, have provided sufficient evidence for 
Europe to start planning for lung cancer screening now; whilst mortality data from NELSON 
are awaited. 
 
This is the rationale for an EU Position Statement (EUPS) that describes the current status 
and sets out the essential elements needed to ensure the development of effective European 
screening programmes. The EUPS expert group comprises individuals from eight European 
countries who have been actively engaged in the planning and execution of the randomised 
controlled European screening trials, those actively engaged with the clinical management of 
patients with lung cancer and lung nodules, and those that have developed relevant clinical 
guidelines; they represent all the specialties and professions involved in delivering successful 
lung cancer screening programmes in Europe. The emphasis for this EU position statement 
focuses on the actual implementation of CT lung cancer screening programmes in Europe by 
radiologists supported by epidemiologists, pulmonologists and thoracic surgeons, in the full 
context of clinical lung cancer diagnosis and treatment. We performed a comprehensive 
literature search for papers on lung cancer screening and through in-depth discussions 
developed this EUPS consensus.  
 
The structure of the EUPS document reflects the evidence addressing the major questions 
concerning the delivery of a successful screening intervention but also highlights the issues 
that still need to be resolved. The contributions to the EUPS were provided by a team of 
clinicians and scientists expert in CT as the method of choice for lung cancer screening. The 
requirement for a EUPS stems from the need to provide European recommendations on CT 
screening that will assist the EU commission and national health agencies in starting planning 
implementation of lung cancer screening within the next two years and to avoid opportunistic 
uncontrolled screening. Since the publication of the NLST results in 2011, it is now crucial 
that we have a EUPS consensus. 
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The focus of the EUPS is limited to lung cancer screening with LDCT and early detection of 
lung nodules prior to clinical work-up, but does not address the entirety of work-up and 
treatment choices. It is highly unlikely that there will be any new randomized controlled 
LDCT screening trials powered to allow conclusions about mortality reduction, so 
recommendations are based on the current evidence. Existing evidence provided by a number 
of studies is sufficient to make recommendations concerning the minimization of false 
positive results in both screen-detected nodules and for clinically detected nodules identified 
in a non-screen environment. The need for non-contrast-enhanced low-dose interval imaging 
should not be considered a false positive test, as the individual is not undergoing an invasive 
clinical workup and therefore the chance of physical harm is very low. Furthermore the 
evidence shows that psychological distress is transient and smoking cessation rates are higher 
amongst subjects requiring interval imaging. 
 
The position statement represents a balance of the available evidence and therefore reflects 
(a) what we have good evidence for, (b) where further evidence is needed to implement 
effective screening programmes, and (c) where practical implications for lung cancer 
screening can already be drawn from current knowledge and state of the art.  
 
1. Current diagnostic tests for lung cancer detection  
 
Computed tomography is the only early detection method suitable for national lung cancer 
screening programmes.  
 
Computed tomography has evolved as the prime method for lung cancer screening. Evidence 
from previous lung cancer screening trials in the 1980’s on chest X-ray with and without 
sputum cytology demonstrated that there was no survival advantage,1,2 and resulted in 
inactivity in this field of research for more than two decades. The first publication in 1999 on 
lung CT screening ignited this modality of lung cancer screening again.3 Other diagnostic 
methods may have a future potential in lung cancer screening but currently there no trials to 
support them.4 
Earlier trials using CT provided evidence, not only for the likely effectiveness, but also a 
great deal about the natural history of the disease. The debate continued about the ability of 
CT screening to reduce mortality until the US National Lung Cancer Screening Trial (NLST), 
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that randomized 53454 subjects was stopped one year earlier than planned because the stop 
criteria of a 20% reduction in lung cancer mortality rate compared with that achieved by 
screening with chest X-ray had been reached in a periodic planned interim analysis; the trial 
also showed a 6.7% reduction in all-cause mortality.5 
 
There is increasing evidence of the effectiveness of CT screening from several pilot trials in 
Europe and from the current NELSON publications, Table 1. However, we need to remain 
aware of the implications and problems associated with the work-up of suspicious nodules 
(i.e. invasiveness of biopsies, waiting time until final decision etc.). 
The high false-positive rates both in the initial screening and subsequent screening rounds, as 
reported in the NLST, need to be reduced to ensure minimal harmful impact on the screenees. 
This is best achieved by accurate interval imaging using the latest and most accurate 
methods, particularly semi-automated volumetric analysis rather than manual maximum 
diameter measurements as already implemented by a number of trials.6–8 Furthermore, the 
definition of false positives also has a major bearing on how we interpret false-positive data. 
NELSON,9 MILD,10 and UKLS7 define false positives from their baseline data, as those 
requiring referral to the pulmonologist and further diagnostic investigation (3.5%), but who 
subsequently did not have lung cancer This is in contrast to the NLST, where every 
individual with a repeat CT scan prior to a repeat annual screen, was considered positive 
(24%, of which 96% were false positive with unnecessary CT examinations and a related 
radiation burden). In NLST, a positive screen included all CTs that showed a nodule 4mm or 
more in diameter and since publication of NLST, the NELSON study has shown that nodules 
smaller than 5mm (or 100mm3) do not confer a greater risk of malignancy at baseline. 
No other technology is currently available that can replace CT screening. Emerging 
technologies need to undergo the same scrutiny that has been applied to CT screening. 
However, if a new emerging technology is considered, it must be compared to CT screening 
in a randomized controlled trial (RCT) and the negative predictive value (NPV) should be 
near 100% and positive predictive value (PPV) should be higher than CT screening. Some 
technologies might be applied as an adjunct to CT screening (see section 3). 
 
2. Outcomes of lung cancer screening trials    
 
The outcomes of lung CT screening trials have impact on implementation. 
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The outcomes of a wide variety of lung cancer screening trials give insight as to how to 
implement lung cancer screening in differing countries in Europe and the optimal set-up for 
population as well as single centre screening in Europe. We have learnt a great deal about 
each stage of the lung cancer CT screening pathway and the management decisions 
required.11 Current trials have provided us with an insight into risk assessment, CT screen 
nodule management, multidisciplinary team (MDT) work-up, surgical interventions, as well 
as psychological impact on the participants and cost effectiveness.  
 
Several nationally funded randomized studies have already been undertaken in Europe 
(DANTE,12 DLCST,13 ITALUNG,14 LUSI,8 MILD,15 NELSON,6 and UKLS.7,16 Their 
results, individually and when pooled, will all contribute to the implementation of CT 
screening in Europe. The only European fully powered RCT that will provide mortality and 
cost effectiveness data is NELSON, although we do have sufficient data to start planning; the 
results from NLST alone have been sufficient for LDCT screening to start in the US and 
Canada.  
 
The incorporation of coronary artery calcification (CAC) score and emphysema assessment 
on LDCT imaging, may enhance the cost-effectiveness and attractiveness LDCT lung cancer 
screening.17 COPD and emphysema are the strongest lung cancer risk predictors and together 
with cardiovascular disease all three imaging biomarkers have a substantial impact not only 
on morbidity but also, independently, on overall mortality.18,19 
 
3. Lung cancer risk prediction modelling  
 
Future Lung cancer CT screening programmes should embrace the use of risk prediction 
modelling to select high risk populations. 
 
The concept of clearly defining the target population for lung cancer screening is gaining 
weight, as selection based only on age, as in most other cancer screening scenarios (e.g. 
breast, colon) is insufficient in lung cancer because of other powerful risk factors, the most 
important of which is exposure to tobacco smoke. The other major risk factors which are now 
also taken into account include; History of respiratory diseases (COPD, emphysema, 
bronchitis, pneumonia and TB), history of previous malignancy, family history of lung cancer 
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(first degree relative greater or less than 60 years), exposure to asbestos. There are several 
published multivariable risk prediction models, but only two have so far been used to select 
subjects for screening in a clinical trial. Risk prediction models have been tested in the NLST 
dataset, demonstrating that the NLST selection criteria could have been improved, including 
the USPSTF recommendations, if a risk model had been implemented.20–22 The LLP risk 
model (LLPv2) is the only risk model used to date to select subjects for a lung cancer 
screening RCT. A higher percentage of participants were identified with lung cancer at 
baseline compared to baseline NLST and NELSON. The cut-off of the LLPv2 model of 5% 
over 5 years is currently being validated in the Liverpool Health Lung Project (LHLP).7,23–25 
The LLP previously compared favourably with the Spitz and Bach models.26 The LLP was 
validated in the UK LLPC cohort with an AUC of 0.82 (CI, 0.80 to 0.85).24 The Bach, Spitz, 
LLP and PLCOm2012 risk models were externally validated in the EPIC-German cohort of 
20,700 ever smokers. The PLCOM2012 model showed the best performance in external 
validation (C-index: 0.81; 95% CI, 0.76-0.86) and the highest sensitivity, specificity, and 
PPV, however, the superiority over the Bach model and the LLP model was considered 
modest by the authors.27 
 
Recently, five different risk models have been compared utilising data from the PLCO and 
NLST datasets.28 Even though a number of sophisticated models have utilised a range of risk 
variables (i.e. family history, previous malignancy, previous respiratory disease, exposure to 
asbestos), the Bach model still proved to have a good sensitivity and specificity,29 and it only 
uses age and smoking history in calculating the risk score, emphasizing the dominance of 
these two risk factors. The PLCO2012 model also provided good results, however, one of the 
limitations of the analysis, is that this model was developed using the PLCO data set, so 
potentially there may be issues of over-fitting. However, all of the models were superior to 
the NLST selection criteria and the current USPSTF recommendations. The predicted risk of 
lung cancer was analysed in 95,882 ever-smokers aged 45 years in the Australian Up Study 
(2006–2009), was calculated using PLCOm2012 applied to baseline data, which showed good 
discrimination (AUC 0.80, 95% CI 0.78–0.81) and excellent calibration.30 Thus, it is essential 
that risk prediction models are used to select subjects for lung cancer screening. Cost 
effectiveness was shown to be improved in the higher risk groups so it follows that better risk 
prediction should also improve costs per life saved. There is no information on related cost 
effectiveness.28 We recognise that the aforementioned risk prediction models were based on 
non-European populations, realizing that lung cancer risk prediction may be influenced by 
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loco regional differences. The EUPS does not recommend any specific risk prediction model, 
however either the PLCO2012 or the LLPv2 would suffice if screening was implemented today. 
 
We have to be aware of the different European healthcare systems and the issues of utilising 
a risk stratification approach (i.e. Germany), where all individuals have a legal right of access 
to the available diagnostic and therapeutic techniques. However, it should be argued that it 
would be unethical to screen low risk patients, based on the harm-benefit considerations. 
 
The risk profile of subjects is a valuable and cost-effective tool to identify those with 
preclinical disease that are eligible for screening.
7,20 Integration of the risk profile with 
biomarker(s) or susceptibility genes could potentially improve the selection of subjects at 
higher level of risk for screening and/or for the management of the disease.31,32  Predictive 
biomarkers, such as microRNA, have been shown as potentially effective tools for the 
identification of susceptible subjects and future lung cancer cases,33–35 whilst bronchial-
airway gene-expression classifier possibly could improve the diagnostic performance of 
bronchoscopy.34 Breath tests for lung cancer have to be considered a strong possibility and 
are currently being tested in a clinical trial.35,36  
  
Identification of new biomarkers for screening will be a reason to implement cooperative 
research; the availability of large, high quality biobanks embedded in screening trials together 
with the radiomics analysis is a future opportunity.  
 
4. Harms and benefits associated with lung cancer screening  
 
There are more benefits than harms from lung cancer screening, when screening is 
undertaken in those with sufficiently high risk 
 
Before implementation of lung cancer screening it should be beyond any doubt that the harms 
associated with lung cancer screening, such as over-diagnosis, surgery for benign lesions, 
psychological harm and radiation exposure are at acceptable levels. 
 
Minimizing harms in CT screening is essential in order to maximize the clinical effectiveness 
of the intervention. Harms may be considered as physical or psychological. The ways in 
which physical harms can be reduced are by (i) ensuring that only those who are at 
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sufficiently high risk to benefit are screened, (ii) reducing screening radiation dose to a 
minimum, (iii) effective management of abnormal findings, including nodules, suspected 
lung cancer and incidental findings. This is predicated on ensuring that there is a high level of 
clinical expertise available so that all aspects of CT screening and management of findings 
are completed to the highest standard. Thus, lung cancer screening should only be undertaken 
according to protocol and screening units and centres should be in a position to ensure 
rigorous quality control. 
 
“LDCT screening can be carried out outside a clinical trial, provided it is offered within a 
dedicated program with quality control, in a centre with experience in CT screening, a large 
volume of thoracic oncology activity and multidisciplinary management of suspicious 
findings” and a well-developed minimally invasive thoracic surgery program. This approach 
is according to the ESMO and ESTS guidelines.37,38  
 
Potential psychological harms can be reduced by the provision of information about CT 
screening presented in a language that is understood by the screenees, as well as detailed 
information concerning abnormal findings, with accurate information about the probability of 
cancer, especially where findings are likely to be benign.  
 
The potential physical harms should be provided to screenees in a clear manner, including 
radiation exposure,39 and harms from biopsy or resection of a benign lesion. However, 
radiation risk is likely to be overestimated, and will in the future be lower with the latest CT 
platforms with ultra-low dose technology. The European trials will provide data which will 
allow for a direct quantification of overdiagnosis. Rates of benign resection vary in clinical 
trials from 10% to at least 25% of total operations.7,10 The consensus is that we should be 
working towards a 10% figure or even lower, however, an optimal percentage has not 
established to date. It should be considered that the patient/physician dynamic is altered in the 
lung cancer screening setting compared to symptomatic individuals who present themselves 
to healthcare institutions.  
 
Effective management includes the benefits of maximizing smoking cessation within CT 
screening programmes. Thus, it is important to inform current smokers of the dangers of 
continuing to smoke for the own general health and to ensure they are offered suitable 
support.40–42 
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5. CT methodologies for early lung cancer detection. 
 
Volume methodology should be utilised for the detection of early lung cancer by CT. 
 
In the NLST trial, a CT screen was regarded as positive if it showed any non-calcified nodule 
at least 4 mm in diameter. The American College of Radiology set up a Lung Cancer 
Screening Committee subgroup to develop Lung-RADS,43,44 in-order to have a quality 
assurance tool to standardize lung cancer screening CT reporting and also provide 
management recommendations. The rationale behind this initiative was the hope that it would 
assist in lung cancer screening CT nodule scan interpretation.  
 
LungRADS performance was compared to the NLST screening trial data,45 which indicated 
that LungRADS substantially reduced the false positive result rate but also the sensitivity 
level decreased. Recently it has been recommended by Mehta et al. indicated that the 
LungRADS system needs to be revised and they faulted the system on the basis that it has 
never been studied in a prospective fashion. In addition, Li et al. have recently analysed the 
size and growth of pulmonary nodules, as a consequence of ‘rounding ’ methodology used in 
LungRADS.46 They concluded that rounding up the mean nodule diameter, which was used 
in LungRADS, increases the frequency of positive results and has a detrimental effect on the 
efficiency of lung cancer screening. Furthermore, LungRADS does not provide guidance on 
risk prediction models. The Brock score47 has been shown to be more accurate than baseline 
LungRADS criteria.48 
 
An alternative method is to determine nodule volume using software for semi-automated 
segmentation, which enables an accurate estimation of nodule size after three-dimensional 
reconstruction (Figure 1). Volumetric analysis of CT detected nodules was initially 
recommended by Henschke et al in 1999,3 and has been further developed and validated 
within the NELSON and the UKLS trial. A recent comparative analysis on both the diameter 
and volume has been undertaken on the NELSON baseline participants with 2,240 non-
calcified nodules. Minimum and maximum diameter within a single nodule varied by a 
median of 2.8mm, which is larger than the LungRADS cut off for nodule growth (increase in 
mean diameter >1.5mm). Nodules with a diameter between 8 to 10mm were represented in 
each of the five differing nodule volume categories (Figure 2).49 
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The recommendation for the future management of CT screen solid nodules is that semi-
automatically derived volume and volume-doubling time should be used in preference to 
diameter measurements; the latter should only be used where volumetry is not technically 
possible. 
 
6. Lung cancer population screening prerequisites  
 
National clinical screening standards are required for future lung cancer CT screening 
programmes. 
 
Accreditation for institutions and radiologists participating in lung cancer CT screening 
should include training and participation in quality assurance.   
 
A central national registry for participants ensures that inclusion criteria are met. In this 
registry, other screening modalities, i.e. CT manufacturer dose, and results together with 
work-up results should be collected, which ensures that previous screens are available and 
quality control can be assured. The institutions providing a lung cancer screening service 
should be registered, have access to a participant registry as well as previous screens, 
providing a certified nodule evaluation software, and will deliver screening results and 
recommendations to the central participant registry. It is recommended that the European 
lung cancer community develop national registries, which potentially could be linked on a 
hub and spoke format, thus enabling international quality control and utilising the data to 
improve the provision of lung cancer screening throughout Europe over time. 
 
National quality assurance boards should be set up which monitors the adherence to 
minimum technical standards and to standardized diagnostic criteria for screen-detected lung 
nodules, similar to the UK and European breast screening programmes,50–52 and are entitled 
to advise /intervene whenever basic requirements are not met. The lung cancer community 
should consider following the example of the Dutch breast screening service by organising 
national ‘Central Reading Centres’ of all CT screening programmes;52 as the local reading of 
CT screen scans would potentially have a major impact on routine radiology service delivery. 
This would also enable ongoing national quality assurance and the introduction of the 
forefront automated pulmonary nodule reading software. 
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Institutions participating in screening programmes require MDTs to be available providing 
access to all relevant specialities (pulmonologist, thoracic surgeon, radiologist, lung cancer 
nurse etc.) in which suspicious screening results may be discussed. They should regularly 
demonstrate to a quality assurance board that they continue to meet basic standards, similar to 
those proposed by RSNA.53   
 
7. Lung nodule management at baseline CT screening   
 
Baseline CT screening programmes should be targeted to prevalent lung nodules. 
 
Management of prevalent lung nodules will largely depend on size criteria. Volumetry is 
essential, but diameter cut-offs will also need to be provided for cases where segmentation is 
not possible. Minimum standards will need to be met for lung cancer screening CT 
acquisition parameters to ensure the standardization of volumetric analysis (i.e. acquisition 
protocol regarding slice thickness, reconstruction interval and image reconstruction algorithm 
(kernel) as well as, clearly defining the low-radiation dose parameters). 
 
Management should be based on the evidence from screening trials that have used volumetry 
such as the NELSON trial. In the original NELSON nodule management protocol, cut-offs 
for negative and positive screen results were 50 and 500mm3, respectively. Nodules within 
volume range of 50-500mm3 were classified as indeterminate. Based on lung cancer 
probability outcome results of the first two screening round of the NELSON study, these cut-
offs could be optimized.54 E.g. for solid nodules <100mm3 return to annual screen (based on 
an annual screening programme), 100-300mm3 for repeat study in 3 months, >300mm3 for 
referral to MDT (Figure 3a).54 Detailed risk profiles have been provided by the NELSON 
group for both nodule volume and volume doubling time (<400 and 400-600 days - increased 
risk described in Figure 3b; no significant increased risk, >600 days), on lung cancer 
probability over a two year period (Figure 4),54 which provides guidance of the future 
follow–up interval for specific screenees. Recently, in-vivo evidence for growth patterns of 
screen-detected lung cancers demonstrated an exponential growth pattern which can be 
described by the VDT.55 Acknowledging that software packages give different estimates of 
solid nodule volume, commonly of the order of 20%, (Corresponding to a non-measurable 
7% error in nodule diameter; absolute 0.4mm error,56 there may be merit in reducing the 
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nodule threshold for a repeat study at 3 months to 80 mm3 if the software is not phantom 
validated (Figure 3c). 
For sub-solid nodules, surveillance should be favoured over intervention to avoid over-
diagnosis. For all pure ground glass nodules and most partial solid nodules, return to annual 
screening will be the most likely recommendation. (Figure 3d).57  Knowledge and data from 
ongoing lung cancer screening projects will also be important for future optimization and 
refinement of nodule management protocols.  
 
It should be noted that morphology assessment will also play a role in the management of 
solid nodules, e.g. clustered ill-defined nodules, which are more in keeping with 
inflammatory aetiology, or smooth peri-fissural nodules or intrapulmonary lymph nodes, 
which will require management not based purely on size criteria.58 There are a number of 
alternative work-up methods of screen-detected suspicious nodules >300mm3 at baseline: i.e. 
core needle biopsy, PET/CT and primary resection.  
 
The management of the patient should be according to the risk of malignancy. As we have 
discussed, lower risk nodules, say those with a <10% risk of malignancy can be followed up 
with interval imaging but those with higher risk need further work-up, provided this is in line 
with the patient’s wishes after an informed discussion. Management options are, broadly, 
further surveillance, biopsy or treatment as the risk of malignancy increases.  
 
The recent ESMO guidelines indicate that the cornerstone of treatment of potentially 
resectable lung cancer is surgical removal of the tumour.37 For those who are not willing to 
accept the risks, or are at very high risk, non-surgical curative therapy should be offered, 
either SABR, hypofractionated high-dose RT or image guided ablative therapy.37 
 
8. Incident screening rounds   
 
The management of lung nodules at incident screening rounds. 
 
Although incident screening rounds will comprise the majority of the work in the early 
detection of lung cancer, until recently, research did not focus on incident nodules and their 
definition. The definition of incident lung nodules has varied widely between LDCT lung 
cancer screening trials.16,59–61 Incident nodules detected in high-risk individuals after baseline 
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screening were either missed previously, or develop de novo in the time interval since the 
prior scan. In the case of a missed nodule, calculation of the volume doubling time is advised 
for further risk stratification. Newly developed nodules, on the other hand, entail a specific 
group of pulmonary nodules distinct from baseline nodules. With an annual incidence 
between 3% and 13% of participants, these nodules are regularly encountered in LDCT lung 
cancer screening.62–65 Contrary to baseline nodules, which may have been present for years 
before detection, new incident nodules are potentially fast-growing.66–69 This is reflected in a 
high cancer risk of 2-8% for participants with a new incident nodule.62,63,65,66 Because these 
nodules have comparably less time to grow before detected, baseline cut-off values are not 
applicable.66 This previously theoretical concept, that led to an adjustment of cut-off values 
for new incident nodules in several trials,45,63,69 has recently been confirmed for new solid 
incident nodules by the NELSON trial.66 Considering that a large proportion (37-57%) of 
new incident nodules are very small (below 50mm3 volume),62,65,66 volume measurement 
should be preferred since diameter measurements are far less precise and reproducible. Data 
from the NELSON trial suggest that new solid incident nodules <27mm3 volume (<1% lung 
cancer probability) represent a low risk group and may return to annual screen (based on an 
annual screening programme), new solid incident nodules 27-207mm3 volume (3% lung 
cancer probability) form an intermediate risk group requiring repeat LDCT in 3 months, and 
new non-calcified solid incident nodules ≥208mm3 volume (17% lung cancer probability) 
form a high risk group requiring referral to MDT.66 We suggest simplifying these categories 
to <30mm3, 30 to 200mm3 and ≥200mm3 (Figure 3b). The existing data indicates that the 
majority (68-86%) of lung cancers found in new incident nodules during lung cancer 
screening are detected at stage I,63,66 volume doubling time assessment at follow-up scans 
appears appropriate, such as outlined in the BTS guidelines.61 However, the current evidence 
body regarding new incident nodules is insufficient and a more standardized manner of 
reporting, for instance strictly separating baseline and incident nodules, could simplify the 
translation to routine clinical management of incidentally detected pulmonary nodules. If a 
previous CT scan <2 years ago is available, recommendations for screen detected new 
incidence nodules could be extrapolated to routine clinical practice in a high-risk patient 
population, similar to the NELSON trial. This has now been adopted from the BTS guideline 
nodule management,70 and in the BTS Quality Standard on Lung Nodule management 




9. Clinical workup of CT detected lung nodules in clinical practice.   
 
In clinical practice the preferred initial and subsequent management should be based on the 
lung cancer probability of the CT detected lung nodules. 
 
Incidentally detected lung nodules are an increasingly common clinical problem arising from 
the increased use of cross-sectional imaging in clinical practice. The British Thoracic Society 
(BTS) has undertaken an in-depth piece of work developing guidelines on the management of 
pulmonary nodules in a clinical context and not in the context of population screening.61 This 
work has been based on extensive review of the literature and the utilisation of recent 
publications from a number of lung cancer CT screening trials and in-depth analysis of the 
data. The Guideline Development Group (GDG) used methodology compliant with AGREE 
Collaboration criteria and standards set by NHS Evidence. The evidence review was 
comprehensive, conducted in November 2012 and updated in June 2014. The guidelines 
provide four management algorithms and two malignancy prediction tools.61 The Brock risk 
prediction tool to calculate malignancy in solid pulmonary nodules ≥5 mm, which are 
unchanged at three months47 and the Herder prediction tool to be used after PET-CT71 
(Figure 3c). 
 
Furthermore, volumetry has been recommended by BTS as the preferred measurement 
method of CT detected nodules. The guideline also provides recommendations for the 
management of nodules with extended volume doubling times. 
 
The BTS guidelines provide recommendations on the use of further imaging, and the use of 
PET-CT information which can be incorporated into pulmonary risk models (Herder model), 
as well as advice on biopsy and the threshold for treatment without histological confirmation. 
BTS provides advice on the information which should be given to patients on the 
management of pulmonary nodules in a non-screening context. The EUPS recommends 
keeping a database of all nodules that can facilitate future refinement of nodule management 






10. Optimal timing of lung cancer screening intervals   
 
Screen interval depends on the baseline and subsequent risk of lung cancer. 
 
The US Preventive Services Task Force (USPSTF) on CT screening has recommended 
screening yearly from the age of 55 to 80 years.72 In a recent NELSON publication, a 2.5 
year screening interval resulted in a significant increase in interval cancers in the fourth 
screening round, thus arguing against using such an interval in a future screening 
programme.73 There were significantly more interval cancers in the 2 year time frame and 
still a trend towards less early stage disease and detailed cost effectiveness of various 
screening scenarios has demonstrated that almost all scenarios are most cost effective when 
screens are annual.74 However, in the NELSON trial, in half of the included participants no 
pulmonary nodules were detected and their 2-year probability of developing lung cancer was 
0∙4%, thereby indicating that a screening interval of up to 2 years, could be considered for 
similar individuals in future screening programmes, a risk stratified approach. The only trial 
to test annual and biennial screening was the MILD trial, where no difference was found in 
terms of mortality when comparing these two screening intervals.75  
 
Screening intervals have been modelled by both the ULKS and IELCAP.76,77 Duffy et al. 
acknowledged the risk of increasing the number of interval cancers but potentially providing 
a more cost-effective approach. Yankelevitz at al.77 argued that we have to move beyond 
hypothesis-testing and on to quantification. We need to learn how the length of the interval 
between screens affects the diagnostic distribution before we consider changing annual 
screening intervals.  
 
Currently we only have trial evidence for annual screening. Recent studies have shown that 
previous negative screening results may provide directions for further risk stratification.78,79 
Future decisions regarding the screen interval timing should be based on risk, psychosocial 
impact,80 cost-effectiveness and the feasibility of implementation,81 but these areas require 
further investigations. However, with newer, ultra-low dose CT techniques, the radiation dose 
for repeated CT screenings over a 30-year period, may not be a major issue for the screenees. 
New developments such as deep learning will assist us in the automation of pulmonary 
nodule management of lung cancer screening.82 
 
 22 
In the future, there will be an issue for screening high risk individuals every year, over a 25 
year period. We should be considering precision medicine in the field of lung cancer 
screening and whether an individual who has had a negative baseline and year one scan, 
should be moved into biennial screening, until their risk profile changes. Lung cancer 
screening is still in an embryonic stage of implementation in Europe and thus we have an 




The EUPS describes the current status of lung cancer screening in Europe. Through 
consensus discussions with experts from the eight European countries undertaking RCT lung 
cancer CT screening trials, we have developed nine recommendations to guide the 
implementation of lung cancer screening in Europe. It is recognised that there remain specific 
areas which require further development and consideration (i.e. integrating smoking cessation 
and selection of the screening population), however, the weight of evidence clearly points to 
the imperative for Europe to start planning for implementation within the next 18 months as 
outlined in the EUPS ‘Call for Action’. During this planning period, the focus for each 
country will be to decide on the best risk prediction methodology to identify and recruit the 
high-risk population and also to set up the required infrastructure for quality controlled CT 
scans, utilising volumetric analysis. The EUPS has provided detailed recommendations on 
the management of lung nodules by lung cancer MDTs, with the aim to minimise harm and 
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Upper figure legend 
A volume growth of 26 % , defined as growth by NELSON criteria, is hardly appreciable by 
diameter measurement (8 % diameter increase which is NO growth by current criteria)  
 
Lower figure legend. 
A 25% diameter increase i.e. threshold for the current growth definition reflects almost a 
doubling in volume ( 95%). It reflects the insensitivity for growth of diameter measurement 
Reproduced from : 
Field et al. Prospects for population screening and diagnosis of lung cancer. Lancet. 
2013;382(9893):732-41. 
 
Figure 2. Range in mean axial nodule diameter per nodule category. Nodules with mean 
diameter between 8 and 10 mm (coloured zone) are represented in each volume category. 
These nodules represent the category with highest uncertainty about nodule nature. The data 
in this figure is based on intermediate-sized baseline nodules only. 
 
 
Figure 3 Nodule Management Protocol 
 
Fig 3a Nodule management protocol for screen detected solid nodules at baseline. 
For nodules with volume-doubling time (VDT) between 400 and 600 days (intermediate 
cancer risk of ~4%), a second repeat CT in 3 months should be considered as an initial 
workup option. 
 
Fig 3b Nodule management protocol for screen detected incidental solid nodules at follow-
up. 
 
Fig 3c Nodule management protocol for clinically detected solid nodules  
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Fig 3d Nodule management protocol for subsolid nodules for both screen detected and 
clinically detected 
 
Figure 3c an 3d reproduced from : 
Callister ME, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, et al. British Thoracic 
Society guidelines for the investigation and management of pulmonary nodules. Thorax. 




Contour plot of the effect of the combined effect of nodule volume and volume doubling 
times on 2-year lung cancer probability. 
Reproduced from:  
Horeweg et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a 
prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet 
Oncol. 2014;15(12):1332-41. 
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Search strategy and selection criteria 
Data for this EU Position Statement were identified searches of PubMed, Medline, and 
references from relevant articles using search terms lung cancer CT screening trial’, ’lung 
screen detected nodules’, ‘lung cancer CT screening recommendations’, ‘lung cancer CT 
screening cost effectiveness’. Abstracts and reports from meetings were included only when 
they related directly to previous published work. Only articles published in English between 
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